Top 3 Messages About JAK Inhibitor Safety Save
Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety.
Transcription
Hi. It's Doctor. Janet Pope reporting at RheumNow from EULAR twenty twenty four in lovely Vienna. I'd like to give you the top three messages about JAK inhibitor safety. So I was part of a debate, and the debate was today on a topic of our regulatory bodies too harsh in the recommendations on JAK inhibitors with respect to safety and restricting prescribing.
And the bottom line that came out of this debate, as well as the data that both David Liu and I reviewed are avoid JAK inhibitors in high risk patients. And there's risk and then there's high risk. So the risk is all kind of relative, so to speak. So the higher risk patients from oral surveillance that was looking at safety was age over 65, ever or heavy or current smoking, high cardiovascular risks, such as already having myocardial events and high malignancy risks, such as smoking, older age and more in men. So the audience voted slightly more than half that the regulations are too harsh.
So what would I say? Top three things. Do a shared decision with the use of JAK inhibitors and use them in caution when appropriate and high risk patients or even medium high risk patients with cardiovascular malignancy risk. Do stratify the risk as some risks are far more relevant. Past MI or revascularization is a lot higher chance of having another MI than borderline high cholesterol or mild hypertension.
And smoking is a big risk. So my call to action is identify who's smoking and try to help the patient stop smoking. That should reduce their cardiovascular risk and it also decreases over time the risk of cancer. Please follow us with lots of reports at RheumNow. Thank you.
And the bottom line that came out of this debate, as well as the data that both David Liu and I reviewed are avoid JAK inhibitors in high risk patients. And there's risk and then there's high risk. So the risk is all kind of relative, so to speak. So the higher risk patients from oral surveillance that was looking at safety was age over 65, ever or heavy or current smoking, high cardiovascular risks, such as already having myocardial events and high malignancy risks, such as smoking, older age and more in men. So the audience voted slightly more than half that the regulations are too harsh.
So what would I say? Top three things. Do a shared decision with the use of JAK inhibitors and use them in caution when appropriate and high risk patients or even medium high risk patients with cardiovascular malignancy risk. Do stratify the risk as some risks are far more relevant. Past MI or revascularization is a lot higher chance of having another MI than borderline high cholesterol or mild hypertension.
And smoking is a big risk. So my call to action is identify who's smoking and try to help the patient stop smoking. That should reduce their cardiovascular risk and it also decreases over time the risk of cancer. Please follow us with lots of reports at RheumNow. Thank you.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.